Effect of Carrelizumab Combined with TACE on Tumor Markers,Angiogenesis Factors and Serum PD-1 and PD-L1 in Patients with Hepatocellular Carcinoma with Microvascular Invasion
Objective:To observe the effects of carrelizumab combined with transcatheter arterial chemoembolization(TACE)on tumor markers,angiogenic factors,serum programmed cell death protein-1(PD-1)and programmed death ligand-1(PD-L1)in patients with hepatocellular carcinoma(HCC)with microvascular invasion.Methods:121 HCC patients with microvascular invasion who were admitted to our hospital from June 2021 to July 2023 were divided into control group(n=60,receiving radical resection of liver cancer and TACE treatment)and study group(n=61,receiving carrelizumab treatment on the basis of control group)according to the random number table method.The efficacy,serum tumor marker levels[alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),abnormal prothrombin(PIVKA-Ⅱ),carbohydrate antigen 199(CA199)],angiogenesis factor levels[vascular endothelial growth factor receptor 2(VEGF-R2),angiopoietin-2(Ang-2),vascular endothelial growth factor(VEGF)],serum PD-1 and PD-L1 levels,adverse reactions were compared between two groups(P＞0.05).Results:Compared with control group,the total clinical effective rate in study group was higher(P＜0.05).Compared with control group after treatment,CEA,AFP,CA199,PIVKA-Ⅱ,VEGF,VEGF-R2,Ang-2,PD-1 and PD-L1 in study group were lower(P＜0.05).There was no difference in the incidence of adverse reactions between two groups(P＞0.05).Conclusion:Carrelizumab combined with TACE in the treatment of HCC patients with microvascular invasion,which can improve the serum tumor markers,inhibit angiogenesis and reduce serum PD-1 and PD-L1 levels,and effectively control disease progression.
NETL
NSTL
万方数据
